As of June 30, 2026, the Company had a total of 1,859,952 shares available for grant under its 2016 Inducement Equity Incentive Plan, 2019 Inducement Equity Incentive Plan, 2024 Equity Incentive Plan and 2025 Inducement Equity Incentive Plan.


	Number of Shares	Weighted- Average Exercise Price
Stock options outstanding at December 31, 2025	2,478,871	$	20.47

Exercised	(137,204)	9.87
Forfeited	(16,591)	17.49
Expired	(27,326)	26.69
Stock options outstanding at June 30, 2026	2,297,750	21.05
Stock options exercisable at June 30, 2026	1,846,811	$	22.81


	Number of Shares	Weighted- Average Grant Date Fair Value
RSUs and PSUs outstanding at December 31, 2025	3,930,939	$	15.54
RSUs granted	1,110,847	20.16
RSUs vested	(1,165,785)	15.01
RSUs forfeited	(506,505)	15.21
PSUs granted	570,634	20.46
PSUs vested	(118,304)	18.99
PSUs forfeited	(70,806)	18.88
RSUs and PSUs outstanding at June 30, 2026	3,751,020	$	17.67

The Company granted PSUs under the stock incentive plans. The PSUs granted to employees include financial and operational vesting metrics to be met over a performance period of three years. The number of shares expected to vest, based on initial grant date expected performance achievement, underlying outstanding PSUs was 651,927 and 226,183 as of June 30, 2026 and December 31, 2025, respectively.

During the six months ended June 30, 2026, the Company granted 570,634 PSUs (“2026 PSUs”) to employees with an aggregate grant date fair value of $11.7 million at target achievement. The 2026 PSUs provide for a performance period from February 1, 2026 through January 31, 2029 to achieve a defined performance metric. The percentage of 2026 PSUs eligible to vest will be determined based on the metric achieved during the performance period and may range from 0% to 200%. As of June 30, 2026, the achievement of the metric was probable, resulting in expense recognition of $2.5 million and $4.1 million for the three and six months ended June 30, 2026, respectively. Compensation expense is being recognized from the grant date through the final vest date of January 31, 2029. The PSU expense for the three and six months ended June 30, 2025 was $0.6 million and $0.8 million, respectively, related to PSUs granted in prior periods.

The Company has an Employee Stock Purchase Plan (the “ESPP”), under which employees can purchase shares of its common stock based on a percentage of their compensation, but not greater than 15% of their respective earnings, provided that an eligible employee’s right to purchase shares of the Company’s common stock may not accrue at a rate which exceeds $25,000 of the fair market value of such shares for each calendar year in which such rights are outstanding. The ESPP has consecutive offering periods of approximately six months in length. The purchase price per share must be equal to the lower of 85% of the fair value of the common stock on the first day of the offering period or on the exercise date.

During the offering period in 2026 that ended on June 30, 2026, 92,553 shares were purchased pursuant to the ESPP for aggregate proceeds of $1.5 million from the issuance of such shares, which occurred on June 30, 2026.

During the offering period in 2025 that ended on December 31, 2025, 61,866 shares were purchased pursuant to the ESPP for aggregate proceeds of $1.0 million from the issuance of such shares, which occurred on January 2, 2026.

The following table summarizes stock-based compensation expense relating to employee and non-employee stock-based awards for the three and six months ended June 30, 2026 and 2025, included in the condensed consolidated statements of operations as follows (in thousands):


	Three Months Ended June 30,				Six Months Ended June 30,
	2026		2025		2026		2025
Cost of testing services	$	200	$	329	$	465	$	692
Cost of product	15		108		104		339
Cost of patient and digital solutions	106		189		240		409
Research and development	1,121		1,407		2,444		2,766
Sales and marketing	1,566		2,146		3,401		4,730
General and administrative	7,646		5,245		13,803		9,419
Total	$	10,654	$	9,424	$	20,457	$	18,355

As of June 30, 2026, unrecognized stock-based compensation expense related to stock options, RSUs, and PSUs was approximately $3.8 million, $37.2 million, and $21.3 million, respectively. The remaining unrecognized compensation cost related to the unvested stock options, RSUs, and PSUs is expected to be recognized over a weighted-average period of 1.84 years, 2.19 years, and 2.43 years, respectively.